Monte Rosa Therapeutics (GLUE) Non-Current Assets (2020 - 2026)

Monte Rosa Therapeutics' Non-Current Assets history runs 7 years deep, the most recent figure standing at $58.9 million for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 3.35% year-over-year to $58.9 million in Q1 2026; TTM through Mar 2026 was $232.5 million, a 7.85% decrease from a year earlier, with the FY2025 full-year figure at $55.5 million, down 9.49% from the prior year.
• Non-Current Assets rose to $58.9 million in Q1 2026 per GLUE's latest filing, from $55.5 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $70.5 million in Q2 2023 and bottomed at $25.6 million in Q1 2022.
• The 5-year median for Non-Current Assets is $63.9 million (2024), against an average of $61.8 million.
• Across the five-year window, Non-Current Assets surged 538.48% in 2022 and fell 10.03% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $66.5 million in 2022, then gained by 1.56% to $67.5 million in 2023, then dropped by 9.25% to $61.3 million in 2024, then retreated by 9.49% to $55.5 million in 2025, then advanced by 6.14% to $58.9 million in 2026.
• Per Business Quant, the three latest GLUE Non-Current Assets figures stand at $58.9 million (Q1 2026), $55.5 million (Q4 2025), and $58.0 million (Q3 2025).